Collegium Pharmaceutical
COLL
198 hedge funds and large institutions have $937M invested in Collegium Pharmaceutical in 2023 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 65 increasing their positions, 63 reducing their positions, and 25 closing their positions.
92% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 25
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15% more capital invested
Capital invested by funds: $816M → $937M (+$120M)
12% more funds holding
Funds holding: 177 → 198 (+21)
9.81% more ownership
Funds ownership: 104.81% → 114.62% (+9.8%)
3% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 63
94% less call options, than puts
Call options by funds: $175K | Put options by funds: $3.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$14.4M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$9.22M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$8.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.24M |
| 5 |
Morgan Stanley
New York
|
+$6.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$6.77M |
| 2 |
Janus Henderson Group
London,
|
-$5.38M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.41M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$3.98M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.89M |
COLL Hedge Fund Activity: Q1 2023 in Review
198 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2023, worth a combined $937M — up 15% from $816M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new COLL positions and 25 closed out — a net gain of 23 holders — while 65 added to existing stakes and 63 trimmed.
The largest buyer was Millennium Management, adding an estimated $14.4M. The largest seller was Intrinsic Edge Capital Management, cutting an estimated $6.77M.
- 198 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2023, up from 177 in Q4 2022.
- Funds reported $937M of Collegium Pharmaceutical stock for Q1 2023, up 15% quarter-over-quarter.
- 48 funds opened new Collegium Pharmaceutical positions in Q1 2023 and 25 closed out, a net change of +23 holders.
- The largest Collegium Pharmaceutical buyer in Q1 2023 was Millennium Management, an estimated $14.4M added.
- The largest Collegium Pharmaceutical seller in Q1 2023 was Intrinsic Edge Capital Management, an estimated $6.77M sold.
Based on aggregated 13F filings for Q1 2023.